5-aza is a chemotherapy drug with activity in leukemia and myelodysplastic syndromes (MDS).
Researchers hope that valproic acid (VPA) and all-trans retinoic acid (ATRA)will increase the
effects of 5-aza. The goal of this clinical research study is to find the highest safe dose
of valproic acid (VPA) that can be given in combination with 5-azacytidine (5-aza) and
all-trans retinoic acid (ATRA) in the treatment of AML and MDS. The safety and effectiveness
of this combination therapy will also be studied.
Additional blood and bone marrow samples will be requested. These samples will be used to
evaluate the effect of the treatment on leukemic cells. In addition, any leftover blood and
bone marrow samples that are collected at the start of the study and during the regularly
scheduled evaluations to be sent for research studies. The research studies will examine
changes in the blood and bone marrow cells that might help explain the causes of leukemia and
MDS and how the combination of 5-aza, VPA, and ATRA works.